US 12,239,701 B2
Respiratory syncytial virus mRNA vaccine
Baek Kim, Atlanta, GA (US); Jack Yoon, Suwanee, GA (US); and David Pak, Suwanee, GA (US)
Assigned to Vernagen, LLC, Tucker, GA (US)
Filed by Vernagen, LLC, Tucker, GA (US)
Filed on Dec. 22, 2023, as Appl. No. 18/394,486.
Claims priority of provisional application 63/483,099, filed on Feb. 3, 2023.
Prior Publication US 2024/0261387 A1, Aug. 8, 2024
Int. Cl. A61K 39/155 (2006.01); A61K 39/00 (2006.01); A61K 39/295 (2006.01); A61P 37/04 (2006.01)
CPC A61K 39/155 (2013.01) [A61K 39/295 (2013.01); A61P 37/04 (2018.01); A61K 2039/53 (2013.01); A61K 2039/70 (2013.01); C12N 2760/18322 (2013.01); C12N 2760/18334 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01)] 27 Claims
OG exemplary drawing
 
1. A respiratory syncytial virus (RSV) vaccine composition comprising
a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding RSV mutant F B strain protein having an amino acid sequence of SEQ ID NO: 1.